Enveric Biosciences Inc

For the period ended Dec 31, 2023. Filed Mar 26, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 26, 2024

ENVB$1.51+4.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

	For the Years Ended December 31,
	2023	2022
Operating expenses
General and administrative	$8,852,021	$11,605,761
Research and development	7,252,437	8,027,773
Impairment of intangible assets and goodwill	—	7,453,662
Depreciation and amortization	343,982	327,910
Total operating expenses	16,448,440	27,415,106
Loss from operations	(16,448,440)	(27,415,106)
Other (expense) income
Inducement expense, net	(1,848,235)	—
Change in fair value of warrant liabilities	94,396	4,315,236
Change in fair value of investment option liability	208,752	3,472,726
Change in fair value of derivative liability	727,000	(325,000)
Interest income (expense), net	3,708	(5,249)
Total other (expense) income	(814,379)	7,457,713
Net loss before income taxes	(17,262,819)	(19,957,393)
Income tax (expense) benefit	(28,913)	1,486,060
Net loss	(17,291,732)	(18,471,333)
Less preferred dividends attributable to non-controlling interest	19,041	33,014
Less deemed dividends attributable to accretion of embedded derivative at redemption value	147,988	295,976
Net loss attributable to shareholders	(17,458,761)	(18,800,323)
Other comprehensive loss
Foreign currency translation	(33,015)	(505,932)
Comprehensive loss	$(17,491,776)	$(19,306,255)
Net loss per share - basic and diluted	$(8.09)	$(13.00)
Weighted average shares outstanding, basic and diluted	2,159,063	1,446,007

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.